JMAR Technologies Marketing Communications Manager Kathi Kirchmeier, 858-946-6800 kkirchmeier@jmar.com or Investor Relations Intl Managing Partner Haris Tajyar, 818-382-9702 htajyar@irintl.com JMAR Technologies, Inc. (OTCBB:JMAR), a leading developer of advanced laser, photonics and detection technologies, today announced the results of a testing program carried out by the U.S. Environmental Protection Agency (EPA) to measure the performance of
JMAR's BioSentry monitoring system and competing products at detecting harmful microorganisms in drinking water distribution systems.
The U.S. EPA presented results at the AWWA Water Security Congress 2008 this week and the tests found that BioSentry was able to detect bacterial pathogens up to 25 times better than any other product tested. The published results can be found in the proceedings of the conference.
The program was carried out in 2007 by the EPA's National Security Homeland Research Center, using a pilot-scale water distribution system at the EPA's testing and evaluation facility in Cincinnati, Ohio. Tests were performed to determine the detection capabilities of BioSentry and other products against intentional introduction of pathogens into a water distribution system. Several pathogen surrogates were used simulating lethal microbes.
JMAR Technologies' President and CEO C. Neil Beer, Ph.D., commented, "As a matter of policy, the EPA does not endorse or promote specific products. However, the performance of our flagship product, BioSentry, in EPA's strictly objective testing program, speaks for itself. These results strongly reinforce our conviction that BioSentry will soon be in wide use around the world to protect the public from intentional or accidental contamination of water supplies. The success of BioSentry also bodes well for other products in development that employ similar advanced technology."
To be added to JMAR Technologies' investor lists, please contact Haris Tajyar at htajyar@irintl.com or at 818-382-9702.
About JMAR
JMAR Technologies, Inc. (OTCBB:JMAR) is a late-stage technology company with expertise in the development and early commercialization of detection and laser-based technologies for nano-scale imaging, chemical and biological analysis, and fabrication. The Company is leveraging more than a decade of laser and photonics research in developing a portfolio of products with market applications in high interest areas such as homeland security, biological monitoring of water quality, and hazardous materials detection. These technologies represent significant intellectual property, including twenty nine issued or pending patents. For further information on JMAR Technologies, please visit www.jmar.com.
Forward Looking Statements: This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. Actual results could differ materially from these forward-looking statements as a result of a number of factors, including the uncertainty of acceptance in the market for our products and technologies or the acceptance of our customers' products or technologies which incorporate our products and technologies, the failure of our technology to perform as predicted, competition from alternative technologies, uncertainties as to the size of the markets, cost and margins for JMAR's products, current or future government regulations affecting the use of JMAR's products, the lack of availability of critical components, the degree of protection from future patents, other risks associated with the development or acquisition of new products or technologies and those risks detailed in the Company's Form 10-K for the year ended December 31, 2007 filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. JMAR Technologies, Inc. does not assume any duty to publicly update or revise the material contained herein.
Product Outperforms All Alternative Technologies for Real-Time
Pathogen Detection
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment